{"protocolSection":{"identificationModule":{"nctId":"NCT00076687","orgStudyIdInfo":{"id":"191622-057"},"organization":{"fullName":"Allergan","class":"INDUSTRY"},"briefTitle":"Safety Study of Botulinum Toxin Type A in Post-Upper Limb Stroke Patients With Reduced Lung Function"},"statusModule":{"statusVerifiedDate":"2011-08","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2003-10"},"primaryCompletionDateStruct":{"date":"2009-08","type":"ACTUAL"},"completionDateStruct":{"date":"2009-08","type":"ACTUAL"},"studyFirstSubmitDate":"2004-01-29","studyFirstSubmitQcDate":"2004-02-25","studyFirstPostDateStruct":{"date":"2004-02-26","type":"ESTIMATED"},"resultsFirstSubmitDate":"2011-07-28","resultsFirstSubmitQcDate":"2011-08-30","resultsFirstPostDateStruct":{"date":"2011-10-03","type":"ESTIMATED"},"lastUpdateSubmitDate":"2011-08-30","lastUpdatePostDateStruct":{"date":"2011-10-03","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Allergan","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"The purpose of this study is to evaluate the safety of injections of botulinum toxin Type A in patients with reduced lung function and focal upper limb poststroke spasticity"},"conditionsModule":{"conditions":["Stroke","Muscle Spasticity","Motor Neuron Disease"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":155,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Biological: botulinum toxin Type A"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Biological: botulinum toxin Type A"]},{"label":"3","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: saline"]}],"interventions":[{"type":"BIOLOGICAL","name":"botulinum toxin Type A","description":"botulinum toxin Type A 240 U injection on Day 1, Week 12, Week 18","armGroupLabels":["1"],"otherNames":["BOTOX®"]},{"type":"BIOLOGICAL","name":"botulinum toxin Type A","description":"botulinum toxin Type A 360 U injection at Day 1, Week 12, Week 18","armGroupLabels":["2"],"otherNames":["BOTOX®"]},{"type":"DRUG","name":"saline","description":"Saline injection at Day 1, Week 12, Week 18","armGroupLabels":["3"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change From Baseline in Forced Vital Capacity (FVC)","description":"Change from baseline in observed FVC. FVC is the maximum amount of air exhaled from the lungs after taking the deepest breath possible. Patients perform three to eight exhalations into a spirometer with the highest value recorded at Baseline and Week 6.","timeFrame":"Baseline, Week 6"},{"measure":"Change From Baseline in Forced Expiratory Volume (FEV1)","description":"Change from baseline in observed FEV1 at one second. FEV1 is the maximum amount of air exhaled in one second. Patients perform three to eight exhalations into a spirometer with the highest value recorded at Baseline and Week 6.","timeFrame":"Baseline, Week 6"}],"secondaryOutcomes":[{"measure":"Change From Baseline in FEV1/FVC Ratio","description":"Change from baseline in FEV1/FVC ratio. This ratio is calculated by dividing the FEV1 value by the FVC value. This represents that portion (or ratio) of FVC exhaled in one second.","timeFrame":"Baseline, Week 6"},{"measure":"Change From Baseline in Ashworth Scale","description":"Change from Baseline in worst upper limb scores using the Ashworth Scale at Week 6 from Baseline. Upper limb includes finger, wrist, thumb, and elbow. Worst score was the highest value measured from the finger, wrist, thumb, or elbow at Baseline and Week 6 based on treated areas. The Ashworth Scale assesses the degree of muscle tone. It is a 5-point scale where 0 equals no increase in muscle tone and 4 equals very severe muscle rigidity. A low score indicates little or no stiffness. A high score indicates severe stiffness. A negative change from baseline score indicates improvement.","timeFrame":"Baseline, Week 6"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Abnormal pulmonary function test results;\n* focal, upper limb spasticity, upper motor neuron syndrome\n\nExclusion Criteria:\n\n* Previous exposure to botulinum toxin of any serotype","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Director","affiliation":"Allergan","role":"STUDY_DIRECTOR"}],"locations":[{"city":"Miami","state":"Florida","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"city":"Prague","country":"Czech Republic","geoPoint":{"lat":50.08804,"lon":14.42076}},{"city":"Szeged","country":"Hungary","geoPoint":{"lat":46.253,"lon":20.14824}},{"city":"Warsaw","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Placebo","description":"Placebo"},{"id":"FG001","title":"Botulinum Toxin Type A 240 U","description":"botulinum toxin Type A 240 U"},{"id":"FG002","title":"Botulinum Toxin Type A 360 U","description":"botulinum toxin Type A 360 U"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"48"},{"groupId":"FG001","numSubjects":"52"},{"groupId":"FG002","numSubjects":"55"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"42"},{"groupId":"FG001","numSubjects":"47"},{"groupId":"FG002","numSubjects":"51"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"4"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Placebo","description":"Placebo"},{"id":"BG001","title":"Botulinum Toxin Type A 240 U","description":"botulinum toxin Type A 240 U"},{"id":"BG002","title":"Botulinum Toxin Type A 360 U","description":"botulinum toxin Type A 360 U"},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"48"},{"groupId":"BG001","value":"52"},{"groupId":"BG002","value":"55"},{"groupId":"BG003","value":"155"}]}],"measures":[{"title":"Age Continuous","paramType":"MEAN","dispersionType":"FULL_RANGE","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"58","lowerLimit":"18","upperLimit":"80"},{"groupId":"BG001","value":"55.5","lowerLimit":"21","upperLimit":"83"},{"groupId":"BG002","value":"55.8","lowerLimit":"19","upperLimit":"81"},{"groupId":"BG003","value":"56.4","lowerLimit":"18","upperLimit":"83"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"21"},{"groupId":"BG003","value":"53"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"29"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"34"},{"groupId":"BG003","value":"102"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Forced Vital Capacity (FVC)","description":"Change from baseline in observed FVC. FVC is the maximum amount of air exhaled from the lungs after taking the deepest breath possible. Patients perform three to eight exhalations into a spirometer with the highest value recorded at Baseline and Week 6.","populationDescription":"Safety","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Liters of air","timeFrame":"Baseline, Week 6","groups":[{"id":"OG000","title":"Placebo","description":"Placebo"},{"id":"OG001","title":"Botulinum Toxin Type A 240 U","description":"botulinum toxin Type A 240 U"},{"id":"OG002","title":"Botulinum Toxin Type A 360 U","description":"botulinum toxin Type A 360 U"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"52"},{"groupId":"OG002","value":"55"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"2.889","spread":"0.7804"},{"groupId":"OG001","value":"3.068","spread":"0.8766"},{"groupId":"OG002","value":"2.923","spread":"0.7627"}]}]},{"title":"Change from Baseline at Week 6","categories":[{"measurements":[{"groupId":"OG000","value":"0.057","spread":"0.3151"},{"groupId":"OG001","value":"0.052","spread":"0.2883"},{"groupId":"OG002","value":"-0.081","spread":"0.2531"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Forced Expiratory Volume (FEV1)","description":"Change from baseline in observed FEV1 at one second. FEV1 is the maximum amount of air exhaled in one second. Patients perform three to eight exhalations into a spirometer with the highest value recorded at Baseline and Week 6.","populationDescription":"Safety","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Liters of air","timeFrame":"Baseline, Week 6","groups":[{"id":"OG000","title":"Placebo","description":"Placebo"},{"id":"OG001","title":"Botulinum Toxin Type A 240 U","description":"botulinum toxin Type A 240 U"},{"id":"OG002","title":"Botulinum Toxin Type A 360 U","description":"botulinum toxin Type A 360 U"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"52"},{"groupId":"OG002","value":"55"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"2.111","spread":"0.5944"},{"groupId":"OG001","value":"2.223","spread":"0.6492"},{"groupId":"OG002","value":"2.168","spread":"0.6568"}]}]},{"title":"Change from Baseline at Week 6","categories":[{"measurements":[{"groupId":"OG000","value":"0.049","spread":"0.1971"},{"groupId":"OG001","value":"0.023","spread":"0.2925"},{"groupId":"OG002","value":"-0.008","spread":"0.2340"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in FEV1/FVC Ratio","description":"Change from baseline in FEV1/FVC ratio. This ratio is calculated by dividing the FEV1 value by the FVC value. This represents that portion (or ratio) of FVC exhaled in one second.","populationDescription":"Safety","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Ratio","timeFrame":"Baseline, Week 6","groups":[{"id":"OG000","title":"Placebo","description":"Placebo"},{"id":"OG001","title":"Botulinum Toxin Type A 240 U","description":"botulinum toxin Type A 240 U"},{"id":"OG002","title":"Botulinum Toxin Type A 360 U","description":"botulinum toxin Type A 360 U"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"52"},{"groupId":"OG002","value":"55"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"0.741","spread":"0.1320"},{"groupId":"OG001","value":"0.731","spread":"0.1260"},{"groupId":"OG002","value":"0.742","spread":"0.1051"}]}]},{"title":"Change from Baseline at Week 6","categories":[{"measurements":[{"groupId":"OG000","value":"0.000","spread":"0.0730"},{"groupId":"OG001","value":"-0.006","spread":"0.0709"},{"groupId":"OG002","value":"0.019","spread":"0.0699"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Ashworth Scale","description":"Change from Baseline in worst upper limb scores using the Ashworth Scale at Week 6 from Baseline. Upper limb includes finger, wrist, thumb, and elbow. Worst score was the highest value measured from the finger, wrist, thumb, or elbow at Baseline and Week 6 based on treated areas. The Ashworth Scale assesses the degree of muscle tone. It is a 5-point scale where 0 equals no increase in muscle tone and 4 equals very severe muscle rigidity. A low score indicates little or no stiffness. A high score indicates severe stiffness. A negative change from baseline score indicates improvement.","populationDescription":"Intent to Treat","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Number on a scale","timeFrame":"Baseline, Week 6","groups":[{"id":"OG000","title":"Placebo","description":"Placebo"},{"id":"OG001","title":"Botulinum Toxin Type A 240 U","description":"botulinum toxin Type A 240 U"},{"id":"OG002","title":"Botulinum Toxin Type A 360 U","description":"botulinum toxin Type A 360 U"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"52"},{"groupId":"OG002","value":"55"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"3.19","spread":"0.607"},{"groupId":"OG001","value":"2.87","spread":"0.561"},{"groupId":"OG002","value":"2.96","spread":"0.693"}]}]},{"title":"Change from Baseline at Week 6","categories":[{"measurements":[{"groupId":"OG000","value":"-0.60","spread":"0.564"},{"groupId":"OG001","value":"-1.01","spread":"0.801"},{"groupId":"OG002","value":"-1.16","spread":"0.834"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","eventGroups":[{"id":"EG000","title":"Placebo","description":"Placebo","seriousNumAffected":7,"seriousNumAtRisk":48,"otherNumAffected":18,"otherNumAtRisk":48},{"id":"EG001","title":"Botulinum Toxin Type A 240 U","description":"botulinum toxin Type A 240 U","seriousNumAffected":9,"seriousNumAtRisk":52,"otherNumAffected":15,"otherNumAtRisk":52},{"id":"EG002","title":"Botulinum Toxin Type A 360 U","description":"botulinum toxin Type A 360 U","seriousNumAffected":6,"seriousNumAtRisk":55,"otherNumAffected":17,"otherNumAtRisk":55}],"seriousEvents":[{"term":"Abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":48},{"groupId":"EG001","numAffected":1,"numAtRisk":52},{"groupId":"EG002","numAffected":0,"numAtRisk":55}]},{"term":"Acute endocarditis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":48},{"groupId":"EG001","numAffected":0,"numAtRisk":52},{"groupId":"EG002","numAffected":1,"numAtRisk":55}]},{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":48},{"groupId":"EG001","numAffected":0,"numAtRisk":52},{"groupId":"EG002","numAffected":1,"numAtRisk":55}]},{"term":"Bacteraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":48},{"groupId":"EG001","numAffected":1,"numAtRisk":52},{"groupId":"EG002","numAffected":0,"numAtRisk":55}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":48},{"groupId":"EG001","numAffected":1,"numAtRisk":52},{"groupId":"EG002","numAffected":0,"numAtRisk":55}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":48},{"groupId":"EG001","numAffected":0,"numAtRisk":52},{"groupId":"EG002","numAffected":1,"numAtRisk":55}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":48},{"groupId":"EG001","numAffected":1,"numAtRisk":52},{"groupId":"EG002","numAffected":0,"numAtRisk":55}]},{"term":"Splenic abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":48},{"groupId":"EG001","numAffected":0,"numAtRisk":52},{"groupId":"EG002","numAffected":0,"numAtRisk":55}]},{"term":"Wound infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":48},{"groupId":"EG001","numAffected":0,"numAtRisk":52},{"groupId":"EG002","numAffected":0,"numAtRisk":55}]},{"term":"Convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":48},{"groupId":"EG001","numAffected":0,"numAtRisk":52},{"groupId":"EG002","numAffected":2,"numAtRisk":55}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":48},{"groupId":"EG001","numAffected":0,"numAtRisk":52},{"groupId":"EG002","numAffected":0,"numAtRisk":55}]},{"term":"Cognitive disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":48},{"groupId":"EG001","numAffected":1,"numAtRisk":52},{"groupId":"EG002","numAffected":0,"numAtRisk":55}]},{"term":"Encephalitis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":48},{"groupId":"EG001","numAffected":1,"numAtRisk":52},{"groupId":"EG002","numAffected":0,"numAtRisk":55}]},{"term":"Epilepsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":48},{"groupId":"EG001","numAffected":1,"numAtRisk":52},{"groupId":"EG002","numAffected":0,"numAtRisk":55}]},{"term":"Ischaemic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":48},{"groupId":"EG001","numAffected":1,"numAtRisk":52},{"groupId":"EG002","numAffected":0,"numAtRisk":55}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":48},{"groupId":"EG001","numAffected":0,"numAtRisk":52},{"groupId":"EG002","numAffected":0,"numAtRisk":55}]},{"term":"Acute coronary syndrome","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":48},{"groupId":"EG001","numAffected":1,"numAtRisk":52},{"groupId":"EG002","numAffected":0,"numAtRisk":55}]},{"term":"Angina Pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":48},{"groupId":"EG001","numAffected":0,"numAtRisk":52},{"groupId":"EG002","numAffected":0,"numAtRisk":55}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":48},{"groupId":"EG001","numAffected":0,"numAtRisk":52},{"groupId":"EG002","numAffected":1,"numAtRisk":55}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":48},{"groupId":"EG001","numAffected":1,"numAtRisk":52},{"groupId":"EG002","numAffected":0,"numAtRisk":55}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":48},{"groupId":"EG001","numAffected":1,"numAtRisk":52},{"groupId":"EG002","numAffected":0,"numAtRisk":55}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":48},{"groupId":"EG001","numAffected":1,"numAtRisk":52},{"groupId":"EG002","numAffected":0,"numAtRisk":55}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":48},{"groupId":"EG001","numAffected":0,"numAtRisk":52},{"groupId":"EG002","numAffected":1,"numAtRisk":55}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":48},{"groupId":"EG001","numAffected":1,"numAtRisk":52},{"groupId":"EG002","numAffected":0,"numAtRisk":55}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":48},{"groupId":"EG001","numAffected":0,"numAtRisk":52},{"groupId":"EG002","numAffected":1,"numAtRisk":55}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":48},{"groupId":"EG001","numAffected":1,"numAtRisk":52},{"groupId":"EG002","numAffected":0,"numAtRisk":55}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":48},{"groupId":"EG001","numAffected":0,"numAtRisk":52},{"groupId":"EG002","numAffected":0,"numAtRisk":55}]},{"term":"Prostate cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":48},{"groupId":"EG001","numAffected":0,"numAtRisk":52},{"groupId":"EG002","numAffected":1,"numAtRisk":55}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":48},{"groupId":"EG001","numAffected":0,"numAtRisk":52},{"groupId":"EG002","numAffected":0,"numAtRisk":55}]},{"term":"Meningocele","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":48},{"groupId":"EG001","numAffected":1,"numAtRisk":52},{"groupId":"EG002","numAffected":0,"numAtRisk":55}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":48},{"groupId":"EG001","numAffected":0,"numAtRisk":52},{"groupId":"EG002","numAffected":1,"numAtRisk":55}]},{"term":"Heart rate decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":48},{"groupId":"EG001","numAffected":1,"numAtRisk":52},{"groupId":"EG002","numAffected":0,"numAtRisk":55}]},{"term":"Mobility decreased","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":48},{"groupId":"EG001","numAffected":0,"numAtRisk":52},{"groupId":"EG002","numAffected":0,"numAtRisk":55}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":48},{"groupId":"EG001","numAffected":0,"numAtRisk":52},{"groupId":"EG002","numAffected":0,"numAtRisk":55}]}],"otherEvents":[{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":48},{"groupId":"EG001","numAffected":1,"numAtRisk":52},{"groupId":"EG002","numAffected":2,"numAtRisk":55}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":48},{"groupId":"EG001","numAffected":1,"numAtRisk":52},{"groupId":"EG002","numAffected":1,"numAtRisk":55}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":48},{"groupId":"EG001","numAffected":4,"numAtRisk":52},{"groupId":"EG002","numAffected":6,"numAtRisk":55}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":48},{"groupId":"EG001","numAffected":0,"numAtRisk":52},{"groupId":"EG002","numAffected":3,"numAtRisk":55}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":48},{"groupId":"EG001","numAffected":3,"numAtRisk":52},{"groupId":"EG002","numAffected":2,"numAtRisk":55}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":48},{"groupId":"EG001","numAffected":0,"numAtRisk":52},{"groupId":"EG002","numAffected":3,"numAtRisk":55}]},{"term":"Muscle spasticity","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":48},{"groupId":"EG001","numAffected":3,"numAtRisk":52},{"groupId":"EG002","numAffected":0,"numAtRisk":55}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":48},{"groupId":"EG001","numAffected":3,"numAtRisk":52},{"groupId":"EG002","numAffected":0,"numAtRisk":55}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo."},"pointOfContact":{"title":"Therapeutic Area Head","organization":"Allergan, Inc.","email":"clinicaltrials@allergan.com","phone":"714-246-4500"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000009128","term":"Muscle Spasticity"},{"id":"D000016472","term":"Motor Neuron Disease"},{"id":"D000000690","term":"Amyotrophic Lateral Sclerosis"}],"ancestors":[{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000009135","term":"Muscular Diseases"},{"id":"D000009140","term":"Musculoskeletal Diseases"},{"id":"D000009122","term":"Muscle Hypertonia"},{"id":"D000020879","term":"Neuromuscular Manifestations"},{"id":"D000009461","term":"Neurologic Manifestations"},{"id":"D000019636","term":"Neurodegenerative Diseases"},{"id":"D000009468","term":"Neuromuscular Diseases"},{"id":"D000013118","term":"Spinal Cord Diseases"},{"id":"D000057177","term":"TDP-43 Proteinopathies"},{"id":"D000057165","term":"Proteostasis Deficiencies"},{"id":"D000008659","term":"Metabolic Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M18569","name":"Motor Neuron Disease","asFound":"Motor Neuron Disease","relevance":"HIGH"},{"id":"M3714","name":"Amyotrophic Lateral Sclerosis","asFound":"Motor Neuron Disease","relevance":"HIGH"},{"id":"M11775","name":"Muscle Spasticity","asFound":"Muscle Spasticity","relevance":"HIGH"},{"id":"M15105","name":"Sclerosis","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M11782","name":"Muscular Diseases","relevance":"LOW"},{"id":"M11787","name":"Musculoskeletal Diseases","relevance":"LOW"},{"id":"M11769","name":"Muscle Hypertonia","relevance":"LOW"},{"id":"M22309","name":"Neuromuscular Manifestations","relevance":"LOW"},{"id":"M12094","name":"Neurologic Manifestations","relevance":"LOW"},{"id":"M21248","name":"Neurodegenerative Diseases","relevance":"LOW"},{"id":"M12101","name":"Neuromuscular Diseases","relevance":"LOW"},{"id":"M15605","name":"Spinal Cord Diseases","relevance":"LOW"},{"id":"M28449","name":"TDP-43 Proteinopathies","relevance":"LOW"},{"id":"M28437","name":"Proteostasis Deficiencies","relevance":"LOW"},{"id":"M11329","name":"Metabolic Diseases","relevance":"LOW"},{"id":"T349","name":"Amyotrophic Lateral Sclerosis","asFound":"Motor Neuron Disease","relevance":"HIGH"},{"id":"T4699","name":"Primary Lateral Sclerosis","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC18","name":"Nutritional and Metabolic Diseases"},{"abbrev":"BC05","name":"Musculoskeletal Diseases"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000001905","term":"Botulinum Toxins"},{"id":"D000019274","term":"Botulinum Toxins, Type A"},{"id":"C000542869","term":"abobotulinumtoxinA"}],"ancestors":[{"id":"D000065087","term":"Acetylcholine Release Inhibitors"},{"id":"D000049990","term":"Membrane Transport Modulators"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000018678","term":"Cholinergic Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000009465","term":"Neuromuscular Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"}],"browseLeaves":[{"id":"M4873","name":"Botulinum Toxins","asFound":"250","relevance":"HIGH"},{"id":"M250157","name":"abobotulinumtoxinA","asFound":"Previous","relevance":"HIGH"},{"id":"M20947","name":"Botulinum Toxins, Type A","asFound":"Previous","relevance":"HIGH"},{"id":"M3163","name":"Acetylcholine","relevance":"LOW"},{"id":"M20448","name":"Cholinergic Agents","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"VaDiAg","name":"Vasodilator Agents"}]}},"hasResults":true}